Diphosphites having an open, 2,4-methylated outer unit and use thereof in hydroformylation.

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.

Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.

Disclosed herein are isotactic polyvinyl ethers and improved methods of making same. The method disclosed herein can produce polyvinyl ethers having a higher isotacticity as compared to polyvinyl ethers prepared with conventional methods.

A particulate nucleating agent is provided and includes an aromatic phosphate ester metal salt represented by a predetermined formula, where the following is satisfied: a maximum particle diameter of the particulate nucleating agent is denoted by D.sub.max and a degree of dispersion of the particulate nucleating agent is denoted by D.sub.p, 80 μm≤D.sub.max≤300 μm and 1.0%≤D.sub.p≤27.0%.

This disclosure relates to uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P.sub.2Y.sub.6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.

The present invention relates to Compounds of Formula (I) or Formula (II):

##STR00001##

or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.

Compounds of the general formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

The present disclosure provides compounds that may be used as ligands in metal-catalyzed reactions, in particular 3,3′-bisilyl biaryl phosphoramidite compounds and processes for preparing the same.